Project Grant R21DA062252
Award Date
6/15/25
Completion Date
5/31/27
Dollars Obligated
$246K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
New Jersey, USA
Similar Awards
This $1,255,890 Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants (CFDA 93.242) program, supports research at Cornell University to investigate the role of cortical GABAergic interneurons in the effects of the psychedelic drug psilocybin. The key objectives are to: 1) use cell type-specific electrophysiology to measure how the three major subtypes of GABAergic interneurons in the mouse medial frontal cortex respond to psilocybin...
The National Institute of Mental Health (NIMH) awarded a $679,118 Project Grant (CFDA 93.242 - Mental Health Research Grants) to the University of California, Santa Cruz (UCSC) to study the cellular and circuit mechanisms underlying the long-lasting therapeutic effects of the psychedelic drug psilocybin in the stressed brain. The project aims to determine how psilocybin affects synaptic plasticity, cortical functional networks, and the representation of behavioral variables in the stressed...
This federal Project Grant award for $708,511 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) will fund a mechanistic trial to elucidate the effects of psilocybin on neural activity in individuals with alcohol use disorder (AUD). The study aims to evaluate the impacts of high-dose versus low-dose psilocybin on AUD patients' neural response to negative affective stimuli and alcohol cues, as well as subsequent drinking...
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $6,489,450.00 to New York University to evaluate psilocybin as an adjunctive treatment for opioid use disorder (OUD) in methadone-maintained patients who continue to use illicit opioids. The study will recruit 240 participants from opioid treatment programs in New York and New Mexico, and will provide psilocybin treatment implemented as...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is funding research at the University of Oregon to investigate the polypharmacology and psychoplastogenic effects of psychedelic drugs using the C. elegans model organism. The overarching goal is to determine how representative psychedelic compounds, which primarily activate serotonin receptors, influence behavior and neuroplasticity in this invertebrate...
This Project Grant award from the National Center for Complementary and Integrative Health (NCCIH), under the federal Research and Training in Complementary and Integrative Health program (CFDA 93.213), will fund a feasibility clinical trial to develop and evaluate a Psilocybin-Assisted Cognitive Behavioral Therapy (PA-CBT) protocol for treating major depressive disorder. The $236,250 award, granted on December 17, 2024, supports a 3-year study to refine and optimize the PA-CBT approach, and...
This federal Project Grant award of $105,570, provided by the National Institute of Justice (NIJ) under the NIJ Research, Evaluation, and Development Project Grants program (CFDA 16.560), supports the development of optimized protocols for the rapid detection, differentiation, and quantification of the psychedelic substances psilocybin and psilocin in food and drink products. The award will fund the creation of an efficient extraction approach for psilocybin and psilocin that is independent of...
This federal Project Grant award of $811,112 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant supports research by the University of California, San Francisco (UCSF) to investigate the brain networks and neural signaling mechanisms that underlie sudden "insight" learning of cue-reward associations. The key objectives are to use advanced techniques like two-photon calcium imaging, high-density...
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $306,556 Project Grant under CFDA 93.286 - "Discovery and Applied Research for Technological Innovations to Improve Human Health" to Interval Therapeutics LLC. The grant supports the development of bioresorbable microdevices that deliver intermittent sub-perceptual doses of 5HT2A agonists, such as psilocybin, to mitigate depression associated with opioid use disorder (OUD). The key aims are to produce...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $1,383,618.00 in funding to The Johns Hopkins University to conduct research on the microglia-mediated adverse effects of cannabis (specifically delta-9-tetrahydrocannabinol or THC) on the maturation of the prefrontal cortex and cognitive function during adolescence. The research aims to elucidate the molecular and cellular mechanisms by which THC...